Current Hematologic Malignancy Reports

, Volume 8, Issue 1, pp 37–42

Management of the New Patient with CML in Chronic Phase

Chronic Leukemias (J Goldman, Section Editor)

DOI: 10.1007/s11899-012-0151-0

Cite this article as:
Marin, D. Curr Hematol Malig Rep (2013) 8: 37. doi:10.1007/s11899-012-0151-0

Abstract

Imatinib has been the preferred initial therapy for newly diagnosed chronic myeloid leukemia (CML) patients for the last 10 years. Today, other tyrosine kinase inhibitors (TKIs) are licensed for first-line use. In this paper we analyze the pros and cons of the various alternatives to imatinib and try to give some advice on the management of the newly diagnosed patient.

Keywords

Imatinib Nilotinib Dasatinib Therapy Chronic myeloid leukemia Side effects 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Haematology, Imperial College LondonHammersmith HospitalLondonUK